Clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy

  • Email
  • Help
Current effective version

Revision 1 - Adopted guideline

Reference numberCPMP/EWP/555/95 Rev. 1
Effective from01/10/2007
KeywordsGrowth factors, myelosuppressive therapy, myeloablative therapy
DescriptionThis document provides guidance for the evaluation of products used to reduce the risk of infection, caused by neutropenia induced by cytotoxic chemotherapy or by myeloablative therapy preceding bone marrow transplantation.

Document history

Revision 1

Current version

Adopted guideline

Overview of comments

Draft guideline

In operation: 01/10/2007–present

Published: 21/03/2007

Published: 27/04/2006

Related content

How helpful is this page?

Average rating:

 Based on 20 ratings

Add your rating:

See all ratings
4 ratings
4 ratings
4 ratings
4 ratings
4 ratings

Tell us more